Hyperthermic Intraperitoneal Chemotherapy

• HIPEC is a specialized cancer treatment involving surgery and heated chemotherapy for abdominal cancers.
• It targets microscopic cancer cells remaining after tumor removal, enhancing chemotherapy’s effectiveness.
• The procedure involves extensive surgery to remove visible tumors, followed by a heated chemotherapy wash.
• Benefits include improved survival rates and local disease control for select patients with peritoneal cancers.
• HIPEC is a complex procedure requiring a multidisciplinary team and is considered for specific cancer types after careful evaluation.

What is Hyperthermic Intraperitoneal Chemotherapy (HIPEC)?

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is a highly specialized cancer treatment that involves delivering heated chemotherapy drugs directly into the abdominal cavity after surgical removal of visible tumors. This approach is primarily used for cancers that have spread to the peritoneum, the membrane lining the abdominal cavity and covering abdominal organs. The goal of this procedure is to eliminate any remaining microscopic cancer cells that may not have been visible or accessible during surgery.

The term Hyperthermic intraperitoneal chemotherapy explained refers to the two key components of this treatment: “hyperthermic,” meaning heated, and “intraperitoneal,” meaning within the abdominal cavity. Heating the chemotherapy solution enhances its ability to penetrate cancer cells and increases the effectiveness of the drugs, while minimizing systemic exposure and associated side effects compared to traditional intravenous chemotherapy. This targeted delivery allows for a higher concentration of chemotherapy directly at the site of the disease.

The HIPEC Treatment Procedure

The HIPEC treatment procedure is a complex, multi-stage process that typically begins with cytoreductive surgery (CRS). During CRS, surgeons meticulously remove all visible tumors and cancerous tissue from the abdominal cavity. This can be a lengthy and intricate operation, often lasting several hours, depending on the extent of the cancer spread. The aim is to achieve “complete cytoreduction,” meaning no visible disease remains.

Immediately following the surgical removal of tumors, the heated chemotherapy phase begins. A specialized perfusion machine circulates a sterile, heated chemotherapy solution (typically between 41°C and 43°C or 105°F and 109°F) throughout the abdominal cavity for a period, usually 60 to 120 minutes. The solution is continuously circulated to ensure even distribution and direct contact with any remaining microscopic cancer cells. After the designated time, the chemotherapy solution is drained from the abdomen, and the surgical incisions are closed. This combined approach aims to maximize the eradication of cancer cells while minimizing damage to healthy tissues.

Benefits of HIPEC Surgery for Cancer

The Benefits of HIPEC surgery for cancer are significant for carefully selected patients, particularly those with peritoneal carcinomatosis originating from colorectal cancer, ovarian cancer, appendiceal cancer, or mesothelioma. One of the primary advantages is improved local disease control. By directly applying high-dose, heated chemotherapy to the abdominal cavity, HIPEC can effectively target and destroy cancer cells that might have been missed during surgery, reducing the risk of recurrence within the abdomen.

Studies have shown that for appropriate candidates, HIPEC, when combined with cytoreductive surgery, can lead to extended survival rates and improved quality of life compared to surgery or systemic chemotherapy alone. For instance, according to the National Cancer Institute, HIPEC has demonstrated improved outcomes for specific types of peritoneal cancers. The localized nature of the treatment also means that the rest of the body is exposed to lower doses of chemotherapy, potentially reducing systemic side effects often associated with traditional intravenous chemotherapy. However, it is important to note that HIPEC is a major procedure with potential risks and is only suitable for a subset of patients whose cancer meets specific criteria and who are in good overall health.